Updated:
Leducq Foundation
The Leducq Foundation was established in 1996 through the estate of Jean Leducq, a French textile industrialist who built a manufacturing fortune before his...
Leducq Foundation
The Leducq Foundation was established in 1996 through the estate of Jean Leducq, a French textile industrialist who built a manufacturing fortune before his death. The foundation's endowment derives from the proceeds of the family business and is governed from dual headquarters in Boston and Paris, reflecting both Leducq's French origins and the foundation's international scope. David Tancredi serves as CEO, leading the foundation's strategic grantmaking operations. Leducq deploys capital exclusively through a structured grantmaking model focused on cardiovascular and neurovascular disease. Its flagship program, the Transatlantic Networks of Excellence, funds multi-institutional research consortia pairing European and North American laboratories — a collaborative model that distinguishes Leducq from single-investigator NIH-style funding. The foundation has supported research into atherosclerosis, heart failure, arrhythmias, and stroke mechanisms. Grantees have included teams at Harvard, INSERM, University of Oxford, and Karolinska Institutet. A separate career development award program funds early-career investigators establishing independent labs. From its Boston and Paris offices, the foundation has committed over $500 million in cumulative grants since inception (per the foundation, 2021). The Transatlantic Networks program accounts for the bulk of deployment, with typical network awards in the $6 million to $7 million range over five years. In addition to its research programs, the foundation maintains the Leducq International Professor award, a single unrestricted grant to an investigator of exceptional distinction. The foundation's board includes both medical and business expertise, ensuring the endowment's corpus is professionally managed. Leducq's structural differentiator is its bi-national governance and its insistence on cross-border collaboration as a condition of funding. Unlike many disease foundations that fund domestic investigators through traditional peer review, Leducq mandates that every major grant involves at least one North American and one European principal investigator working jointly. This condition creates a durable research network that persists beyond individual grant cycles, a design feature embedded from the foundation's founding charter (per the foundation's official communications).
General information
Firm type
Limited Partner
Year founded
1996
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Additional offices
Paris, France
Principals
David Tancredi
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs the Leducq Foundation's investment and grantmaking decisions?
David Tancredi serves as Chief Executive Officer, overseeing both the endowment's asset management and the foundation's grantmaking operations. The foundation maintains a board of directors that includes medical scientists and financial professionals who guide investment policy for the endowment corpus. Day-to-day grant administration is handled by program staff in Boston and Paris.
How does Leducq source research proposals?
Leducq issues competitive calls for proposals for its Transatlantic Networks of Excellence program, which requires applications from at least one North American and one European principal investigator. The foundation also administers career development awards for early-career researchers. Proposals undergo scientific peer review managed by the foundation's scientific advisory committee, a panel of external cardiovascular experts.
Is Leducq a single-family office or a grantmaking foundation?
Leducq operates strictly as a charitable foundation under US 501(c)(3) and French equivalent status, not a family office. It does not make for-profit investments, venture deals, or direct company investments. Its capital is deployed exclusively through charitable grants to academic and nonprofit research institutions.
Does Leducq make venture investments or for-profit allocations?
No. Leducq is a pure grantmaking foundation. Unlike some endowed foundations that operate direct investment programs or mission-related venture arms, Leducq's structure confines deployment to charitable grants funding academic medical research. The endowment corpus is managed for total return but no program-related investments or equity stakes in portfolio companies have been disclosed.
What investment stages or research phases does Leducq fund?
Leducq funds basic and translational cardiovascular research exclusively, from mechanistic discovery to preclinical proof-of-concept. The Transatlantic Networks program targets established laboratories with a track record, while career development awards support early independent investigators. The foundation does not fund clinical trials, late-stage drug development, or commercial medical device testing.
Where does the Leducq Foundation's wealth originate?
The foundation's endowment was seeded with the estate of Jean Leducq, a French industrialist who built a textile manufacturing business. The Leducq family textile operations generated the wealth that capitalizes the foundation's grantmaking and investment corpus.
How is Leducq's governance structured between Boston and Paris?
The foundation maintains legal entities and physical offices in both Boston and Paris, a structure reflecting Jean Leducq's French heritage and the foundation's transatlantic research mandate. Grants are administered jointly, and the board includes representation from both regions. This dual-headquarters model is rare among disease foundations and central to Leducq's identity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: